Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Breast Neoplasms 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × CX 5461 × Genitourinary × Clear all
NCT04890613 2026-04-28

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Senhwa Biosciences, Inc.

Phase 1 Recruiting
52 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡